Imperial College London
Alternate

ProfessorJaneDavies

Faculty of Medicine, National Heart & Lung Institute

Professor of Paediatric Respirology & Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 7973j.c.davies

 
 
//

Assistant

 

Mrs Gina Rivellini +44 (0)20 7594 7986

 
//

Location

 

G44Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@inbook{Davies:2019:10.1016/B978-0-323-44887-1.00053-5,
author = {Davies, G and Griesenbach, U and Alton, E and Davies, JC},
booktitle = {Kendig's Disorders of the Respiratory Tract in Children},
doi = {10.1016/B978-0-323-44887-1.00053-5},
pages = {800--811.e3},
title = {53 - Molecular Therapies for Cystic Fibrosis},
url = {http://dx.doi.org/10.1016/B978-0-323-44887-1.00053-5},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - CHAP
AB  - This chapter describes the therapeutic strategies for cystic fibrosis which are based on targeting cystic fibrosis transmembrane conductance regulator (CFTR), either at the gene or protein level. We provide updates on small molecule CFTR modulators and gene therapy, focusing on clinical development and evaluation. The field has seen significant progress over recent years, particularly with the CFTR potentiator, ivacaftor, in patients with class III mutations. Increased understanding of the abnormalities in the structure and function of CFTR protein will help optimize the approaches required for normalizing function and, in doing so, aid the rational design of clinical trials-both in terms of the development of more efficacious drugs and the selection of appropriate patient populations. While progress with gene therapy remains some way behind, potential benefits (including being mutation agnostic and a nonsystemic route of delivery) remain significant. It may be that future optimal approaches will harness the benefits of more than one of these approaches and lead to considerable synergy. The ultimate goal for molecular and advanced therapies in cystic fibrosis is to find drugs or combinations of drugs capable of restoring CFTR function, applicable to patients with any genetic mutation.
AU  - Davies,G
AU  - Griesenbach,U
AU  - Alton,E
AU  - Davies,JC
DO  - 10.1016/B978-0-323-44887-1.00053-5
EP  - 811
PY  - 2019///
SN  - 9780323448871
SP  - 800
TI  - 53 - Molecular Therapies for Cystic Fibrosis
T1  - Kendig's Disorders of the Respiratory Tract in Children
UR  - http://dx.doi.org/10.1016/B978-0-323-44887-1.00053-5
ER  -
Download